Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.
Lue webcast- ja audiocast-lähetysten transkriptejä
Lue webcast- ja audiocast-lähetysten transkriptejä
Huomio: Tämä on koneellisesti luotu transkripti ja se saattaa sisältää epätarkkuuksia.
Afternoon, everyone. Depending on where you are joining us today for the Biotage 2024 earnings call. My name is Frederic Vanderhaegen, CEO of Biotage. I joined the company a little more than six weeks ago, and I'm thrilled to share with you our solid Q3 2024 results. Joining me today on the call is Andrew Kellett, our CFO. Here's the agenda for the call today. After a short summary of who we are as a company, I will provide the highlights for the Q3 results, and Andrew will second me in detailing those. I'm thrilled to join the company as Biotage has a very resilient business model. It offers equipment, services, and consumables that address the sample preparation challenges across multiple markets, from applied markets such as forensic, food, and environmental, all the way to drug discovery and development for the biopharma industry in that particular market. We have solutions from discovery all the way up to downstream processing. Biotage has continued to evolve its portfolio to capture market opportunities from small molecules to the new modalities. We are pleased to announce that Q3 has posted results that are aligned with the consensus on revenue and EBITDA. Biotage delivered a solid 12% organic growth over the prior year and a 9% reported growth. Australia is now completed, reported as organic. Our recurrent revenue from services and consumables continues to drive our overall results, while our equipment sales remain somewhat weaker, driven by China and conservative spending from our pharma customers in Europe. As many others have commented, we are seeing some customers deferring equipment spending decisions to the next quarter. For us, we have made some progress in addressing our backlog in peptide synthesis, but the demand continues to outpace our current manufacturing capabilities. As we speak, we continue exploring solutions to address this. A short note on our revenue split from a geographical perspective. North America posted strong results, benefiting from a diversified portfolio of businesses.
In.
That region. The analytical, testing, and diagnostic business is delivering steady growth year over year. We are also progressing well on our priorities. We did rescale our OpEx in China to a new normal. We are continuing to expand in areas needed to support our growth, such as expanding our manufacturing sites as demand increases, aiming to commission the site in October. We are also. We also opened a new clean room facility in Canton, near Boston, Massachusetts, which will help us attract the attractive column packing markets. Lastly, we are pleased with the progress made in the market with the product we recently launched. Like a toxin layer used for endotoxin removal. Astro Adept trial to adoption focuses on early adopters, which is a high-flow technology for lentiviral vector purification. We have recently launched our Biotage Select LCD detectors, which have been very well received in the market, and we continue addressing the opportunities in testing with the media that is well received from a customer's point of view. I would be remiss if I didn't close by mentioning that we have signed up for the SBTi targets through the third quarter. Let me now turn it over to Andrew, who will provide you with more color on our financials.
Thank you. Thank you, Frederic.
Good morning, everybody. The Q3 report along with the presentation is now available on our website in the investor section under financial reports. The business had a good Q3 performance. We delivered positive organic growth of 12% and had strong recurring revenues. Our underlying EBITDA was ahead of last year, and we were super efficient at turning that Adjusted EBITDA into cash. Our business is in good shape and built on solid foundations. Our small molecule and analytical diagnostic testing businesses deliver predictable revenue streams, industry-leading gross margins, and solid underlying EBITDA and cash generation. Our large molecule business gives us access to the high-growth bioprocessing market and the ability to generate superior revenue growth and attractive margins. Coupled with our expansive modality offering, our enviable broad suite of innovative 'must-have' solutions and a balanced geographical profile, this gives us an attractive competitive offering. In the quarter, we saw similar trends to what we've seen and communicated throughout the year, with gradual momentum building in our key Americas and EMEA markets, and continued headwinds in China. Our drug discovery and development business delivered reported revenues of 349 million SEK, up 13%, or 16% organically for the quarter. For the first nine months of the year, it delivered reported revenues of just over 1 billion SEK, up 25%, or 4% organically. We are working at pace with our supply partner to resolve the previously reported production constraints for our peptide systems, while we are gradually seeing a sequential quarter-on-quarter increase in production capacity. There is still work to be done to match supply with the current level of demand, which is holding back some reported growth in this area. Our analytical and diagnostic testing business delivered reported revenues of $141 million in the quarter, up 1%, and 5% organically for the first nine months of the year. It delivered reported revenues of $451 million, up 12% or 14% organically.
In the.
Quarter. Geographically, our core Western markets of America and EMEA accounted for 86% of total revenue, with APAC accounting for 14%. China represents less than 5% of our revenue. In Q3, we had recurring revenues of 351 million, representing 72% of total revenue, up 20% over Q3 '23. We saw FX headwinds in Q3 of approximately 50 million SEK, or 3%, holding back our revenue growth.
The.
For the first nine months of the year. Geographically, our core Western markets of the Americas and EMEA accounted for 85% of total revenue, with APAC accounting for 15%. So, we saw a very similar trend in Q3. We had recurring revenues of just under 1.1 billion SEK, again representing 72% of total revenue, which was up 39% over 2023. Our gross margins at 63% year to date are robust and ahead of last year. In the quarter, which is traditionally quieter, we did see some transitory changes in product and customer mix. What I would say is do not get too fixated on one particular quarter as our business goes along. Yes, margins in Q3 were a little lighter, but in Q2 they were a little stronger, with an average of 63%. Importantly, we continued to deliver attractive adjusted EBITDA. In fact, in Q3, we delivered an adjusted EBITDA of $124 million, up 6% over Q3 2023. In the first nine months, we've delivered adjusted EBITDA of $380 million, 17% above 2023. In Q3, we delivered adjusted cash flow from operations of $153 million, up 18%, representing 124% of adjusted EBITDA. For the first nine months, we delivered adjusted cash flow from operations of $399 million, up 61%, representing 105% of adjusted EBITDA, demonstrating clearly our ability to successfully convert profits into physical cash. We finished the quarter with gross cash of $370 million and net cash of $120 million for the year. So far, we've funded acquisition earnout payments of approximately $220 million, dividends of $128 million, and investments in intangible and tangible assets of $132 million, totaling approximately $480 million. In total, we've been able to do that because we generate good margins, good profitability, and importantly, we can convert that profit into cash. We continue to invest in our operational facilities to increase manufacturing capacity to enable future attractive growth in the Isle of Man. Additional capacity will come on stream in Q4. In Boston, our new facility has clean rooms so we can more fully exploit the column packing market as well as warehousing for rapid delivery of products to our customers. Additionally, our continued investment in research and development underpins our steady stream of product launches and cements our reputation for thought and innovation leadership in the markets we operate in. To conclude, we've delivered a very solid Q3 and year-to-date performance, and the business is in good shape as we enter Q4. Nothing in this Q3 announcement alters our view of the business. The fundamentals are super strong, and Biotage is well placed. We're confident of delivering on our full year '24 targets, and we're now open for questions. Operator. We are now open for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Carl Norén from SEB. Please go ahead.
Yes.
Hello and good morning, Frederic and Andrew. A couple of questions from my side. If we start on the gross margin here in the quarter, as you mentioned, Andrew, it's a little weaker than what we've seen before. You say it's driven by the mix. I'm just wondering if you could be a bit more explicit and tell us a bit about what is driving here in the quarter? Because it seems like instrument sales are still down and consumables are growing. So I'm just wondering a bit if you could comment on the gross margin.
Yeah. I mean, it’s just that we saw some transitory changes, particularly in our service business, which ebbs and flows. Sometimes we have a pickup in the amount of work we have to do under our service contracts. So, you know, on a quarterly basis, it evens itself out, but can move around within the quarter. Also, you know, we had a few variations, as the mix can be slightly different in Q3. It doesn't alter our view of the full year. Year to date, we're at 63. So I wouldn't consider just Q3 as a harbinger of weaker margins. We don't believe there's anything in our business that suggests that. So we still feel confident that we're going to see margin growth year on year. And we have done so, and we will continue to see that. So, I wouldn't read too much into the slightly lighter Q3 gross margin and say that we are able to protect the EBITDA. We're good at converting that EBITDA into cash. So, I know it's been a bit of commentary this morning on the Q3 margin. I wouldn't read much into that and see it as the beginning of some sort of trend. No, it's not.
It's very clear. And just to follow up on that, the Australian gross margin. Is it possible to say anything about whether that was accretive or dilutive to the gross margin in this quarter?
Accretive. Yeah, we will see. You will see. You'll start to see. Yeah. The gross margin is now higher, and we expect that trend to continue.
That's good. And it leads into my next question here as we're heading into the seasonally strong Q4 for Australia. So I'm just wondering a little bit how we should think here going into the fourth quarter. I mean, you said historically that seasonality should decrease, but I guess we should still expect quite a big ramp-up here sequentially in Q4. So, do you expect to be able to reach close to last year's Q4 interim in the Large Molecules segment?
Yes, I know what you and others have projected for Australia. We're not shying away from that. Um, you know, we've got a solid business. We've got a good pipeline, and we've got a backlog. So, yeah, I mean, absolutely, we are super excited about the Australia business. Um, you know, it's got great potential, a great growth trajectory. So, yes, the Australia business is growing over 70% on a year-by-year basis. Um, yeah. And we still think, you know, there’s plenty in the tank yet. So, you know, in Q4, say, the numbers that are out there for Q4, we're comfortable with.
Sounds good. And then, the last question on the analytical testing business. I think it seems to be down a little bit compared to the previous quarters. I'm just wondering if there's anything specifically impacting that business. At least, according to my numbers. It looks a bit softer than what I've seen before.
Yes, I think, particularly with the analytical testing business, Carl, it's noteworthy that we have a very strong position in the Americas, specifically in the US. Yeah. And typically, within Q3 the holiday period, it can get quieter. Um, it can get quieter. So, you know, I think it's just that it's a particularly quieter quarter for the analytical testing where we are selling into the US Pathlabs.
Yeah, that's great. And just the final one, if I may, on the gross margin again for the full year. I mean, you're down to 63% now, year to date. Do you think that's a fair assumption for the full year as well? Around 63.
Well, we think there is, you know, a bit of legs left yet in that.
Okay.
That's great. Thank you for answering my questions. Andrew and Frederik, have a good day. Good luck.
Thank you.
The next question comes from Ludvig Lundgren from Nordea. Please go ahead.
Yeah. Hi. Frederic and Andrew. So, three questions from me, if I may. Um, so continuing a bit here on Austria. I noticed sequential growth continues in the Americas, or at least when looking at the large molecules segment as a whole. I assume that, like with this process chromatography offering, new customers typically order small columns and then eventually scale up. Could you elaborate a bit on what type of customers are currently buying these products in the US?
Yeah, I think that's the question. So we are fortunate to have a solid business that addresses multiple modalities. We are targeting plasma customers, but also targeting those who are addressing large molecules such as monoclonal antibodies. But we have also been active in expanding our customer base within the cell and gene therapies for lentivirus cleaning and endotoxin removal. So we have a pretty steady strategy that aims to expand the number of customers to whom we sell the product. And you are straight to the point; we need to see it before the process development occurs so that when the customers adopt the technologies and ramp up later in production, we can ensure a steady stream of revenue throughout the life cycle of the molecule. So, that's the strategy. And I think the strategy has proven to be successful so far.
Okay. But then specifically, would you say that order volumes are typically smaller in the US compared to Europe, for example, currently?
No, actually, on the contrary, we are performing well. Well, in the US. I think this is a global industry. So there's a lot of early seeding that can occur in one geography. Ultimately, the pharmaceutical industry may decide to conduct a technology transfer to another geography or operate through a Contract Manufacturing Organization (CMO). So again, I would reiterate what is important to the business, which is to ensure that the process development, sometimes occurring in the US and sometimes in Europe, ultimately leads to revenue in other geographies. So I think what is important is not so much where the revenue occurs at a small scale, but whether or not we are penetrating the downstream processing. From that perspective, the more molecules we get specified, the more likely we are to see one of them materialize into revenue. The revenue can come from Europe, the US, or Asia. Uh.
Okay. Thanks. That's very clear. Um, and then a bit on equipment, I suppose it was up sequentially here in Q3, but I suppose it's never negatively affected by China. Would it be possible to elaborate a bit on this business excluding this region, and also maybe if this is mainly related to small molecules, or the split between small molecules and analytical testing.
Yes.
Analytical testing is characterized by a higher share of recurrent revenue. So it's pretty steady from that perspective. And it's contributing to strong growth in America, given the nature of the space we operate in that region. When it comes to equipment specifically, it's true that the biggest contributors to the equipment decline are still coming from China. As we compare to the prior year, we think that we have bottomed out right now in China. And that’s what I said. We have rescaled our operating expenses to this new normal. I would just say, as we think about Europe, it's mostly about the scale-up of small molecules that we have observed. This is against Project Ray, which grows mostly. And it's a business that's a little more volatile when it comes to those aspects. The fundamentals of the business remain solid, but customers don't change columns on a large scale for small molecule flash chromatography every other week. So I think you need to see that business as being a little bit more volatile. But it's coming from the small molecule.
That's true.
Yeah. Okay, thanks. Um, and then finally, just on the peptide synthesizer business, you had a backlog, I think, of $35,000,000 in Q1. And, saying that your production is sequentially improving now, is the current order intake somewhat in line with production, or is the order book still building here, or how should we view this? Yeah.
So I think we have seen a huge demand. I think it's well known that the industry is very much into peptides and building peptide libraries. I think we have seen an increase in demand, substantially higher than what we have been able to address through our ramp up in manufacturing. We have increased our production capacity by 50% with our partners. But it's nowhere near what we see the market potential can be. So I think we are working diligently with our partners and exploring various opportunities for us to continue expanding. Or opportunities to capture market share there.
They've got a backlog.
A backlog. You know, although we are kind of increasing that capacity. Our backlog is at similar levels. So yeah, it's clear that we can't get them out quickly enough.
Okay. Thanks. That's helpful. Thanks for taking my questions.
The next question comes from Matthias Hedblom from Handelsbanken. Please go ahead.
Yes. Good morning. Two questions from me, please. The cost initiatives in China. Can we quantify what that means in terms of numbers or structure? And then, secondly for you, Fredrik, in the CEO statement you mentioned sharpening the strategy. Any early thoughts on what that entails or when we can expect more on that topic?
I mean, we regularly, really look at our businesses all the time. China is obviously a particular focus for that business to remain profitable. You know, we've taken measures to reduce headcount. Our aim is to align our cost structure as a percentage of our revenue with pre-COVID levels. And, you know, we will be getting there in Q4. Um, so, you know, yes, China is a declining business, but we still have a business there. Um, you know, we are looking into a new way of doing business.
The.
New way of doing business in China. And what does that entail for us? What do we need to do? What returns can we make? But obviously, in the immediate term, we have taken immediate cost actions to align its cost structure with the business it currently has. We will continue to do that in every business we operate to ensure that we are trading profitably.
Yeah. And I guess the question was about sharpening the vision and the strategy of the company. I think this is a great company. We say we want to address all the modalities from small molecule all the way up to new modalities. This is a pretty broad space when it comes to new modalities. As you know, today we have worked on seven gene therapies. With Astra, we have worked on two monoclonal antibodies. We have worked on two peptides. Oligonucleotides. I think we need to recognize that we will always be limited in terms of resources. So sharpening the strategy and the vision for the business really means thinking about which markets are rapidly growing and how we can leverage our technologies to penetrate these markets in the applied sector without becoming diluted. So I think we've provided a couple of examples of the progress we're making. Most of them are front end to mass spectrometry. If I were to describe those that can address multiple applied opportunities, both in the US and in Europe. And if we consider small molecule drug discovery and development, I think we'd like to build on the fast-growing segments, the attractive ones, but also the ones that are large in scale. So, as illustrative of that, the monoclonal antibodies market is a very large one that we aim to address. Oligos. Peptides are also a very attractive market that we have building blocks to strategically continue building upon. So I think that's what I mean by sharpening the strategy, just defining across the multiple modalities where we have a technology that we can build upon, and where the market is attractive and growing, and where we can take and leverage our go-to-market strategy to really engage with the customers. There are some segments where we are a little bit less present that I would deprioritize over those segments.
And a quick follow-up, if I may. Andrew, is it possible to quantify the portion of sales that comes out of China? Is it less than 5% in this quarter or year to date? It is. Absolutely.
Yeah. Yes. China. China is. Yeah. As I mentioned before, China. China. You know, it's a slight headache for us as it is for all. But for many other businesses, such as tech and so on, it's a major migraine for us. Yeah. We are seeing declines. But it's a small part of our business now. Very manageable. Um, so yeah, from the heady days of 15% plus we're down to less than five.
Attempting to follow up on my customer base in Europe who are holding back instrumentation orders this quarter. What's the confidence in that coming across in the fourth quarter? And there are already signs of orders placed in October. Or is that dependent on the final part of the quarter, which is typically the case.
We historically have a backlog view as we enter the quarter. So, the backlog is at a similar level as the prior year and prior quarter. So I think, and as we go through the quarters, we have a funnel. We review the opportunities diligently with our commercial team. Historically, we always saw an order flush at the quarter and year end. Historically, we have also seen that last year, we did not anticipate that. So we are reasonably prudent as we look at the business, and we will probably have to work with our customers to make sure that when we have opportunities, we capture them. But I can't tell you the level of certainty whether or not those customers will place the order. So I think it is an ongoing process of opportunities to review. I think we haven't lost opportunities, which is a very good sign. It depends on the customers to release their budget.
That's very helpful. Thanks so much.
The next question comes from Carl Nguyen from CIB. Please go ahead.
Yes. Hi, John. I just had a follow-up on the peptides. I didn't really hear what you said there, but could you just comment on the deliveries you've had here, of the backlog in Q3? And how do you think that will be higher in the fourth quarter compared to Q3?
I think we increased our delivery by 50% over what our history was. I think we believe we have reached a plateau that is driven by the resources and manufacturing capability that our partner currently has. So we don't envision that Q4 will be higher than what it is. Our ability to deliver in quarter three. It is a journey. We have started to increase. We have to continue working with the partners to get to the next plateau of production. We believe the market is attractive and large enough for us to continue expanding into that field. And that's what we're working on. But it doesn't occur overnight. So I think that we need to find the resource. We need to find the materials. We need to train the people. It's a steady, steady ramp up. But I would take a conservative view for quarter four, which would be that we won’t be doing less than what we have done in quarter three.
And obviously, just as we commented earlier, the backlog remains the same. So while we are increasing production, the backlog is maintained, if not slightly increasing. So, you know, that just tells us there's some great demand out there.
Yeah.
And just another one on the small molecule side. I mean, looking at the numbers here, it looks like America's back to growth again, while EMEA is a bit weaker. Can you comment on the overall demand trends within small molecules? Are you seeing a continued strong comeback in demand, or has it leveled off, what would you say?
I think we are, as I said, if we strip out the component of China and the scale of countries, I would say Europe would be, probably not as solid as the US is right now, but flat to moderate growth already. So, we are by no means just a small molecule company. We will be driving growth as much as the new modalities. I think that's well known. All the large molecules are addressing large therapeutic areas that small molecules cannot. But we believe the worst is behind us.
Yeah. If you look at the organic decline in system sales in Q2, it was around minus ten and it's now approximately minus five. So, we are seeing light. You know, it is easing. You know, we just see that it continues to start easing further. So I think, you know, I never say never, but we think that the worst is behind us now. Hopefully, we'll start turning that around and dropping that minus in front of the number soon.
Yeah. Okay. And one question on the level of personnel in the company. I just noticed there was a slight increase in the quarter, with 675 employees. Do you think you will remain approximately at that level in the coming quarters, or do you see an immediate need to increase the headcount?
I think we will add resources for the critical gaps that we may have in order to execute the strategy, but we'll continue being mindful about how the business can evolve, or what could be the volatility in some of the areas of the business. And we adjust resources to the business so that we can continue delivering strong results.
Here. Thank you.
The next question comes from Ludvig Lundgren from Nordia. Please go ahead. Ludvig Lundgren Nordia. Your line is now unmuted. Please go ahead.
That one for me as well, if I may. So, just looking at the history of bookings here for Q4, I think you typically book these manufacturing slots ahead. Could you elaborate a bit on how this is looking compared to last year? Um.
Yes, I mean, it's a similar profile. Um, you know, we, um, yes. I mean, I don't think there's anything different from what we've been seeing from last year and into this year. I mean, the plant is running well. We've got some good bookings. They have solid bookings. We've got a very solid pipeline that we are expecting to close progressively as we go through the quarter. So, there's no new news. It's, you know, business as usual.
If I may add, I think I had the privilege to review the final report with the commercial leaders. I think they have a very robust process, very good customer intimacy to understand what is needed by the customers and when, which enabled the site to level-load at its capacity and allocate the slots appropriately. We are able to address the demand as it occurs.
Okay. Thanks. Sounds good.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments. Please go ahead.
Um, well, thank you all. Apologies for the slight delay in starting the conference, but, hopefully, we've shown that we've delivered some very solid Q3 results. Organically, our business has grown 12%. I'm sure if you cast your net around the market, you'll struggle to find businesses delivering organic growth of 12%. You know, we've advanced, and we're delivering solid year-to-date gross margins, up from last year. We're delivering solid adjusted EBITDA generation, up both in the quarter and year-on-year. And very, very importantly, we are turning those profits into cash. Our cash generation is above our adjusted EBITDA. I think we're going into Q4 very confident. There's nothing in this announcement and results that suggests that we're shying away from our targets. You know, we are very well placed. The fundamentals of the market are very strong. I believe Biotage is very well positioned. And, you know, we're very lucky, I think, to have, you know, to attract the caliber of Frederic Vanderhaegen and his experience and knowledge of the market into our business, and I'm sure that's going to have a major positive effect as we go into Q4 and in future years. So thank you very much for joining us.



















